US 12,473,326 B2
Crystalline forms of dexamethasone dimers and uses thereof
Ian Charles Parrag, Mississauga (CA); Matthew Alexander John Statham, Milton (CA); Emma-Louise Elizabeth Moore, Mississauga (CA); Bahareh Khalili, Mississauga (CA); Judith Anne Williams, Toronto (CA); Elizabeth Poloz, Kitchener (CA); and Boris Gorin, Oakville (CA)
Assigned to Ripple Therapeutics Corporation, Toronto (CA)
Appl. No. 17/426,779
Filed by Ripple Therapeutics Corporation, Toronto (CA)
PCT Filed Jan. 31, 2020, PCT No. PCT/CA2020/050117
§ 371(c)(1), (2) Date Jul. 29, 2021,
PCT Pub. No. WO2020/154815, PCT Pub. Date Aug. 6, 2020.
Application 17/426,779 is a continuation in part of application No. PCT/CA2019/050136, filed on Feb. 1, 2019.
Claims priority of provisional application 62/883,170, filed on Aug. 6, 2019.
Prior Publication US 2022/0089635 A1, Mar. 24, 2022
Int. Cl. C07J 5/00 (2006.01); A61K 8/00 (2006.01); A61P 19/02 (2006.01); B29C 35/02 (2006.01); B29C 49/00 (2006.01); B29K 105/00 (2006.01)
CPC C07J 5/0076 (2013.01) [A61K 8/00 (2013.01); A61P 19/02 (2018.01); B29C 35/02 (2013.01); B29C 49/0006 (2022.05); B29K 2105/0035 (2013.01); C07B 2200/13 (2013.01)] 12 Claims
 
1. A solid crystalline form of a compound represented by the following formula:

OG Complex Work Unit Chemistry
the solid crystalline form being characterized by an X-ray powder diffraction (XRPD) pattern comprising peaks at: 3.8°±0.2° 2θ, 7.6°±0.2° 2θ, 8.8°±0.2° 2θ, 9.72±0.2° 2θ, and 12.2°±0.2° 2θ.